March 29, 2012 10:23 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Stifel Nicolaus raises its price target on Buy-rated Allergan (NYSE: AGN) from $90 to $110 on takeaways from the company's R&D day suggesting future sources of growth. Stifel Nicolaus says, " The company laid out several near term opportunities with the release ofpositive Phase III data and filing in idiopathic OAB as the biggest surprise, which we believe will begin generating growth in the near term. Additionally, Allergan introduced a new bio-compatible surgical mesh, SeriScaffold, for launch in 2013. However, the most valuable programs, in our view, are the longer term investments the company has made in Botox for osteoarthritis (a new area), targeted toxin for neuropathic pain, anti-VEGF to treat the large markets of aged-related macular degeneration, and bimatoprost for hair loss. With the revenue potential of these programs, Allergan's long-term growth is tangible and sustainable."AGN closed at $94.05 a share on Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.